Fig. 1.

Survivin inhibitors MX106 and MX107 synergize with genotoxic treatments in suppressing tumor cell growth. (A) High survivin levels are associated with poor prognosis in patients with breast cancer. Data were retrieved from KMplot.com. (Left) Kaplan–Meier analyses of overall survival in patients with breast cancer stratified by BIRC5 levels. (Right) Kaplan–Meier analyses of recurrence-free survival in TNBC patients based on BIRC5 levels. (B) MDA-MB-231 cells were treated with varying doses of MX106 or MX107 for 24 hours. Cell viability was determined by the CCK-8 assay. The IC₅₀ values of MX106 and MX107 were 2.2 and 3.1 μM, respectively. (C) MDA-MB-231 cells were treated with Dox alone or in combination with MX106 for 24 hours. Cell viability was analyzed as in (B). (D) CI values of combination treatment of MX106 and Dox in MDA-MB-231 cells were calculated and plotted using CompuSyn. (E) The combination effect of MX106 with Dox in U2OS cells was analyzed as in (C). The IC₅₀ value of Dox alone was 3.4 ng/ml and decreased to 0.6 ng/ml when combined with MX106 treatment. (F) MDA-MB-231 cells were treated with IR alone or in combination with pretreatment of MX106 (1 µM) for 12 hours. Cell viability was determined at 48 hours after radiation. CCK-8, Cell Counting Kit 8; HR, hazard ratio; OS, overall survival; RFS, relapse-free survival.